Between the Lines Podcast: Tazemetostat in Relapsed/Refractory Follicular Lymphoma
Expert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.
As part of the Between the Lines™ video series, Bruce Cheson, MD, FACP, FAAAS, FASCO, a board certified hematologist at the Center for Cancer and Blood Disorders in Bethesda, Maryland, spoke with Steven Park, MD, an oncologist and vice chair of Research at the Atrium Health Levine Cancer Institute and a clinical professor of Medicine at Wake Forest University. These experts shared their insight on the phase 1/2 E7438-G000-101 (NCT01897571) clinical trial and highlighted key data on tazemetostat (Tazverik), an EZH2 inhibitor, in relapsed or refractory follicular lymphoma.
In the video series, Cheson and Park discussed the following:
- Overview of relapsed/refractory follicular lymphoma and available treatment options
- Tazemetostat trial data and propensity score-matched analysis
- Role of tazemetostat treatment moving forward
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts,Spotify, or anywhere podcasts are available.
Zanubrutinib Combo Improves ORR Vs Obinutuzumab in Follicular Lymphoma
October 24th 2023The primary end point of overall response rate is met in the phase 2 ROSEWOOD study of patients with relapsed/refractory follicular lymphoma receiving zanubrutinib plus obinutuzumab vs obinutuzumab monotherapy.
Epcoritamab Produces Positive Responses in R/R Follicular Lymphoma
July 1st 2023Investigators of the phase 1/2 EPCORE NHL-1 trial plan to discuss their findings with global regulatory authorities to determine the next steps for epcoritamab in the treatment of relapsed/refractory follicular lymphoma.
